Results 21 to 30 of about 60,209 (283)

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology

open access: yesPharmaceutics, 2021
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as ...
Amelia-Naomi Sabo   +5 more
doaj   +1 more source

Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex

open access: yesFrontiers in Cell and Developmental Biology, 2022
Mammalian target of rapamycin (mTOR) inhibitors (sirolimus or everolimus) have been demonstrated effective in reducing the size of tuberous sclerosis complex (TSC)-associated retinal astrocytic hamartoma (RAH) in short term.
Chen-Xi Zhang   +6 more
doaj   +1 more source

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

open access: yes, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly   +9 more
core   +1 more source

Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis

open access: yesOrphanet Journal of Rare Diseases, 2021
Background Patients with lymphangioleiomyomatosis (LAM) frequently experience pneumothorax. Although sirolimus is the standard therapy for LAM, its effect on pneumothorax is controversial.
Teiko Sakurai   +8 more
doaj   +1 more source

Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solid-phase extraction [PDF]

open access: yes, 2002
Quantification of the new immunosuppressant sirolimus (syn. rapamycin; Rapamune((R))) in whole blood by chromatography is essential for its clinical use since no immunoassay is available although monitoring is mandatory.
Fleischer, Claudia   +5 more
core   +1 more source

Sirolimus-Induced Angioedema [PDF]

open access: yesAmerican Journal of Transplantation, 2004
Sirolimus (SRL) is a macrolide immunosuppressant that has gained widespread use in organ transplantation. Its full spectrum of side-effects is yet to be defined. We describe herein three cases of SRL-induced angioedema (AE) in African-American (AA) primary renal allograft recipients who received SRL in combination with mycophenolate mofetil and ...
Hani M. Wadei   +8 more
openaire   +3 more sources

Enhanced Supersaturation and Oral Absorption of Sirolimus Using an Amorphous Solid Dispersion Based on Eudragit® E

open access: yesMolecules, 2015
The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral ...
Youngseok Cho   +5 more
doaj   +1 more source

Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. [PDF]

open access: yes, 2012
The immunosuppressive drugs used to prevent the rejection of transplanted organs have a narrow therapeutic index. Under treatment results in episodes of rejection leading to either damage or loss of the organ. Over immunosuppression increases the risk of
Abboudi, H, Macphee, IA
core   +2 more sources

Pitfall in the high-throughput quantification of whole blood cyclosporin A using liquid chromatography-tandem mass spectrometry [PDF]

open access: yes, 2005
In a growing number of laboratories the technique of liquid chromatography-tandem mass spectrometry is used for the quantification of cyclosporin A in whole blood, employing cyclosporin D as the internal standard. Cyclosporin A is extensively metabolized
Spöhrer, Ute, Vogeser, Michael
core   +2 more sources

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease [PDF]

open access: yes, 2018
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in ...
Arcaro, Alexandre   +10 more
core   +2 more sources

Home - About - Disclaimer - Privacy